Paclitaxel and bevacizumab in first-line treatment for HER2-negative metastatic breast cancer: single-center experience
- 398 Downloads
The aim of our analysis was to report the outcome and safety of patients treated with bevacizumab and paclitaxel as first-line treatment for HER2-negative metastatic breast cancer. Between February 2009 and August 2011, 62 consecutive patients received paclitaxel 90 mg/m2 on days 1, 8, and 15 and bevacizumab (BV) 10 mg/kg intravenously on days 1 and 15, every 28-day cycle. After 6 cycles of combined treatment, patients were given maintenance BV every 3 weeks (15 mg/kg) until progression disease or unacceptable toxicity. At time of analysis, median overall survival was 12.3 months (range 4.6–44.8 months), progression-free survival was 8.1 months (range 2.3–33.2 months), and time to treatment failure was 8.4 months (range 2.3–33.2 months). Our results confirmed the efficacy and the acceptable toxicity profile of bevacizumab plus paclitaxel as first-line regimen for metastatic breast cancer.
KeywordsBreast cancer Metastatic breast carcinoma Bevacizumab Paclitaxel Chemotherapy
This study was not funded by any source, and the authors have nothing to disclose
Conflict of interest
The authors declare that they have no conflict of interest.
- 3.Robert NJ, Dieras V, Glaspy J, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol. 2011;29:1252–60.PubMedCrossRefGoogle Scholar
- 8.Sweeney CJ, Miller KD, Sissons SE, et al. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res. 2001;61:3369–72.PubMedGoogle Scholar
- 12.Pritchard KI, Thomssen C, Pierga JY, et al. Final overall survival results, including analysis of patients with triple-negative disease and aged ≥ 70 years, from the ATHENA study evaluating first-line bevacizumab-containing therapy for locally recurrent/metastatic breast cancer. Cancer Res. 2010;70(24 suppl):236s.CrossRefGoogle Scholar